Acambis Smallpox Vaccine Contract Could Carry 30% To 40% Profit Margins
Executive Summary
Acambis foresees profit margins in the range of 30% to 40% from its contract with the Department of Health & Human Services to stockpile 155 mil. doses of smallpox vaccine
You may also be interested in...
Anthrax Vaccine Timetable Is Reasonable, GAO Finds; Aventis Protest Denied
HHS' next-generation anthrax vaccine development deadlines are reasonable, the General Accounting Office said in a rejection of an Aventis-Pasteur protest
Anthrax Vaccine Timetable Is Reasonable, GAO Finds; Aventis Protest Denied
HHS' next-generation anthrax vaccine development deadlines are reasonable, the General Accounting Office said in a rejection of an Aventis-Pasteur protest
Next-Gen Smallpox, Anthrax Vaccines To Be First Use Of Animal Efficacy
A next-generation smallpox vaccine is expected to be the first product licensed under FDA's animal efficacy rule, HHS Office of the Assistant Secretary for Public Health Emergency Preparedness Senior Advisor Philip Russell, MD, said Aug. 28